Paradigm Capital Management Inc. NY Invests $17.08 Million in Bath & Body Works, Inc. $BBWI

Key Points

• Paradigm Capital Management acquired 738,400 Bath & Body Works shares worth approximately $17.08 million, representing about 0.37% of the company. Institutional investors collectively own 95.14% of BBWI.
• Bath & Body Works exceeded quarterly expectations with $0.32 EPS versus a $0.29 estimate and $1.38 billion in revenue, though sales declined 3.2% year over year. The company reaffirmed 2026 guidance of $2.40–$2.65 EPS.
• The company declared a quarterly dividend of $0.20 per share, equal to a 4.2% yield at the reported share price. Analysts maintain a consensus “Hold” rating with an average price target of $22.57, compared with shares opening at $19.16.

Paradigm Capital Management Inc. NY acquired a new stake in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 738,400 shares of the company's stock, valued at approximately $17,079,000. Paradigm Capital Management Inc. NY owned approximately 0.37% of Bath & Body Works at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of BBWI. Global Retirement Partners LLC bought a new position in Bath & Body Works in the fourth quarter valued at approximately $31,000. Activest Wealth Management bought a new stake in shares of Bath & Body Works during the fourth quarter worth $32,000. Geneos Wealth Management Inc. increased its position in shares of Bath & Body Works by 217.7% during the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock worth $35,000 after acquiring an additional 801 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Bath & Body Works by 42.6% during the fourth quarter. Parallel Advisors LLC now owns 1,897 shares of the company's stock worth $38,000 after acquiring an additional 567 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Bath & Body Works during the third quarter worth $39,000. 95.14% of the stock is owned by institutional investors.

Bath & Body Works Price Performance

Shares of NYSE BBWI opened at $19.16 on Tuesday. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 5.38, a PEG ratio of 1.92 and a beta of 1.38. The business has a 50-day moving average of $20.46 and a 200-day moving average of $20.06. Bath & Body Works, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $32.32.

Bath & Body Works (NYSE:BBWI - Get Free Report) last released its earnings results on Wednesday, May 27th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.03. The business had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.36 billion. Bath & Body Works had a negative return on equity of 45.34% and a net margin of 10.03%.Bath & Body Works's revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.49 earnings per share. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, sell-side analysts expect that Bath & Body Works, Inc. will post 2.63 EPS for the current year.

Bath & Body Works Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Friday, August 21st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 21st. Bath & Body Works's dividend payout ratio is presently 22.47%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. TD Cowen boosted their price objective on shares of Bath & Body Works from $20.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, May 28th. Citigroup raised Bath & Body Works from a "neutral" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Tuesday, August 18th. Jefferies Financial Group boosted their price target on Bath & Body Works from $22.00 to $23.00 and gave the company a "hold" rating in a report on Tuesday, July 28th. UBS Group reaffirmed a "neutral" rating on shares of Bath & Body Works in a research report on Wednesday, August 19th. Finally, Barclays dropped their target price on Bath & Body Works from $25.00 to $23.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 28th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $22.57.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source